

pSELECT-NGFP-zeo

Plasmid for the expression of GFP-N-terminal tagged proteins

Catalog code: psetz-ngfp

For research use only

Version 20K30-MM

PRODUCT INFORMATION

Content:

- 20 µg of pSELECT-NGFP-zeo plasmid provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

Product is shipped at room temperature. Lyophilized DNA should be resuspended upon receipt and stored at -20°C. Lyophilized DNA is stable 3 months at -20°C. Resuspended DNA is stable more than one year at -20°C.

Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

Plasmid construct has been confirmed by restriction analysis and sequencing. Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pSELECT plasmids are specifically designed for strong and constitutive expression of a gene of interest in a wide variety of cell lines. They allow the selection of stable transfecants and offer a variety of selectable markers. pSELECT plasmids contain two expression cassettes: the first drives the expression of the gene of interest and the second drives the expression of a large choice of dominant selectable markers for both *E. coli* and mammalian cells. They are both terminating with a strong polyadenylation signal (polyA) that separates the two expression cassettes thus preventing any transcription interference. The late SV40 polyA terminates the transcription of the gene of interest while the human β-globin polyA terminates the transcription of the selectable marker.

pSELECT-Tag is a new family of expression plasmids designed to generate tagged proteins in order to facilitate their detection and/or purification. pSELECT-Tag features three well-known tags: the green fluorescent protein (GFP) gene, the human influenza hemagglutinin (HA) epitope and the polyhistidine (His) tag. The GFP gene encodes a green fluorescent protein that absorbs blue light (major peak at 480 nm) and emits green light (major peak at 505 nm). pSELECT-Tag plasmids allow to add the tag either at the N or C terminus of the protein of interest. N-terminal tag: the tag encompasses the Start codon and is followed by a multiple cloning site (MCS). pSELECT-NGFP-zeo can also be used as a control plasmid for pSELECT-GFP-LC3.

PLASMID FEATURES

First expression cassette

• **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.

- **MCS:** The multiple cloning site contains the following restriction sites: 5' - BamH I, Eco47III, Neo I, NheI - 3'

Each restriction site is compatible with many other enzymes.

- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.

- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

Second expression cassette

- **CMV enh/prom:** The human cytomegalovirus immediate-early gene 1 promoter/enhancer was originally isolated from the Towne strain and was found to be stronger than any other viral promoters.

- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

- **Sh ble gene** confers zeocin resistance. The *Sh ble* gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.

- **BGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.


CLONING STRATEGY

For expression of a tagged protein, it is important to ensure to clone your gene-of-interest into the correct reading frame. In general it is recommended to use Bam HI/Nhe I restriction site combination for cloning into plasmids with the N-Tag. For the plasmids with N-Tag, check whether your gene of interest and the start codon of the N-Tag are in the correct reading frame.

Note: The Bam HI restriction site is compatible with Bgl II.



If it is not possible to use the Nhe I restriction site, it is possible to use another restriction site such as Neo I.



Alternatively, blunt end cloning can be achieved using the Eco 47 III site, which is downstream of the Bam HI site. Blunt end PCR fragments can be obtained using T4 DNA polymerase or Klenow.



TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

References:

1. Kim, D.W. *et al.* (1990). Gene 2: 217-223.
2. Takebe, Y. *et al.* (1988). Mol. Cell Biol. 1: 466-472.
3. Carswell, S., and Alwine, J.C. (1989). Mol. Cell Biol. 10: 4248-4258.
4. Yu J & Russell JE. (2001). Mol Cell Biol, 21(17):5879-88.

RELATED PRODUCTS

Product	Catalog Code
pSELECT-NGFP-blasti	psetb-ngfp
pSELECT-CGFP-blasti	psetb-cgfp
pSELECT-CGFP-zeo	psetz-cgfp
pSELECT-NHA-blasti	psetb-nha
pSELECT-CHA-blasti	psetb-cha
pSELECT-NHA-zeo	psetz-nha
pSELECT-CHA-zeo	psetz-cha
pSELECT-CHis-blasti	psetb-chis
pSELECT-NHis-zeo	psetz-nhis
pSELECT-CHis-zeo	psetz-chis

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



NotI (-1)

1 **GC**GGCCG**C**AATAAAATCTTATTTCATTACATCTGTGTTGGTTTG**T**GTAACTAACA**TAC**
 75 GCTCTCCATCAAAACAAA**ACGAA**ACAAA**ACTAGC**AAA**TAGGCT**GTCCCCAGTG**CAAGT**GCAGGTGCCAG

SgfI (171)

149 AACATTCTCTATCGA**AGGAT**TCGATCG**CTCG**CGGTGCCGT**CAGT**GGCAGAGCG**CACAT**CGCCACAGTCC
 223 CCGAGAAGTTGGGGGAGGGTCGG**CAATT**GAACGG**GTGC**CTAGAGAAGGTGGCGGGGTAA**ACT**GGGAAAG
 296 TGATGTC**GT**TACTGG**CTCC**GGCTTTCCCAGGGTGGGGAGAACCGTATATAAGT**GCAGT**AGTCGGTGA

HindIII (410)

370 ACGTTCTTT**CG**CAACGGTTGCCAGAACACAG**CTGA**AGCT**GGCT**CG**ATCT**CC**TT**CACGC
 444 GCCCGCCGCC**TAC**CTGAGGCC**CATCC**ACGCCGG**TTGAGT**CG**GTCT**GCC**GCCTCC**GG**CTGT**GG**TC**
 518 CTGA**ACT**CG**GTCC**GG**CGT**TAG**GTAA**AG**TTAA**AG**CTCAG**GT**CGAGACC**GG**GC**TT**GTCC**GG**CGCT**CC**TT**GG**A**
 592 GC**CTAC**CT**TA**GA**CTCAG**CCGG**CTCT**CC**ACG**CT**TC**GG**CTGAC**CC**GT**CT**CA**CT**TAC**GT**CTT**GT**TT**CG**TT**

BspHI (725)

666 TCTGTT**CT**CG**CC**GT**TAC**AG**AT**CC**AA**AG**CT**GT**GA**CC**GG**CG**CT****AC**CT**GA**GA**TC**AC**CG**CA**AG**GG**A**
 740 GAAGAA**CT**TT**ACT**GG**GT**TT**GT**CC**AA**TT**CT**GG**TT**GAG**CT**GG**AT**GG**GT**AT**GT**GA**AT**GG**CC**AC**AA**TT**CT**GT
 814 GT**CTGGT**GA**AGGT**GA**AGGAG**AT**GCA**CT**AT**GG**AA**AG**CT**GA**AG**TT**CATT**GT**AC**CA**AC**AG**GA**AG**CT**GC
 888 CAGTGC**CT**GG**CC**AA**CT**CTGG**GT**AC**CC**AC**CC**CT**GA**CT**AT**GG**GT**CA**AT**GT**TT**CAG**CAGG**TAC**CC**GT**AC**CA**CAT**G
 962 AAGCAG**CAT**GA**CT**CT**AA**AT**CT**GC**AA**GT**GG**TT**AT**GT**TC**AG**GG**AG**AG**GA**CA**AT**CT**CT**AA**AG**GT**GA
 1036 TG**GA**AA**TT**AT**AA**AG**AC**AG**GG**CAG**AA**GT**GA**AG**GT**TT**GA**GG**GT**AT**AC**CT**GG**TT**AC**AG**GA**AT**TT**GA**GG**GA
 1110 TT**GAT**TT**TA**AG**GA**AG**AT**GG**AA**AC**AT**CT**GG**GT**CAC**AG**CT**GG**AG**TAC**AA**CT**AT**AT**CT**CAC**AA**AT**GT**TT**AC**ATT
 1184 AT**GG**CAG**ATA**AG**CAG**GA**AT**GG**AA**TT**TA**AG**GT**CA**AT**TT**CA**AG**AT**TA**AG**AC**AC**AT**GG**AG**AT**GT**GT**CC
 1258 ACT**GG**CAG**AC**ATT**AC**AG**CAG**AA**AC**AC**CC**CT**AT**GG**GT**AT**GG**CC**AG**TT**CT**CC**CT**CC**AG**AT**AA**CT**AC**AT**CT**CA
 1332 G**CA**CT**CA**AT**CT**GT**CT**GT**CC**AA**AG**AC**CC**TA**AT**GG**AG**AA**AG**AC**AC**AT**GG**TC**CT**GT**GA**GT**TT**GT**AC**AG**CA**
 202**er** Thr Gl nSer Al aLeuSer LysAspProAsnGl uLysArgAspHi sMet vAl LeuLeuGl uPheVal Thr Al a

PstI (1457)

Eco47III (1453) NheI (1469)

BamHI (1447) NcoI (1463)

1406 GCAGGAATTACT**CT**GG**GA**AT**GG**AT**GG**AT**GAG**CT**GT**ACA**AG**GG**GAG**GT**GG**AT**CC**AG**CG**CT**GC**AG**CC**AT**GG****G**CT**AG**GT**GG**
 227**Al** a**Gl** y**l** e**Thr** Leu**Gl** y**Me** t**Asp****Gl** u**Leu****Tyr****Lys****Gl** y**Gl** y**Ser** **Ser****Al** a**Al** a**Al** a**Met****Gl** y**•••** —

1480 CAGACAT**GATA**AG**ATAC**ATT**GATG**AG**TTGG**AC**AAAC**AC**ACA**ACT**AGA**AT**GC**AG**TG**AAAAAA**AT**GT**TT**AT**TT**GT

1554 GAAATT**GT**GAT**GCT**ATT**GCTT**AT**TTG**TA**ACC**ATT**ATA**AG**GT**CA**ATAA**AC**AG**TT**AA**AC**AC**AA**AT**TC**CAT**

1628 TC**AT**TT**TA**GT**TT**CAG**GGT**CAG**GGG**GAG**GT**GG**GAG**TT**TTAA**AG**CA**GT**AAA**AC**CT**TAC**AA**AT**GT**GG**TA**

EcoRI (1703)

1702 T**GG**AATT**CT**AA**AA**AT**AC**AG**CAT**AG**CAA**AC**TT**AA**CT**CC**AA**AT**CA**AG**CC**CT**TA**CT**GT**GA**AT**CC**TT**CT**GA**GG**GA**
 1776 T**GA**ATA**AG**GC**AT**AG**GC**AT**CAG**GG**GCT**GT**TG**CC**AA**AT**GT**GC**AT**AG**CT**GT**TT**GC**AG**CC**CT**AC**CT**TT**CAT**GG**GAG**

1850 T**TT**AA**AG**AT**AT**GT**GT**AT**TT**CC**AA**AG**GT**TT**GA**ACT**AG**CT**CT**CA**TT**CT**TT**AT**GT**TT**AA**AT**GC**AC**CT**GC**AC**CT**CC**

SspI (1942)

1924 CACATTCCCTTTAGTAAAATATTCAAGAAATAATTAAATACATTGCAATGAAAATAATGTTTTATT
 1998 AGGCAGAATCCAGATGCTCAAGGCCCTCATAATATCCCCAGTTAGTAGTTGGACTTAGGAAACAAGGAAC
 2072 CTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTCTAGCTTATCCTCAGTCCTGCCACAAAGTGC
 2146 ACGCAGTGCCTGGCGGGTGGCGAGGGCGAACCTCCGCCACGGCTGCTGCCATCGGTATGCCGG
 115 1 al CysAsnGl yAl aProAspArgLeuAl aPheGl uArgGl yTrpProGl nGl uGl y l eGl uThr Me tAl aPro
 2220 CCCGGAGGCCTCCGGAAAGTTCGTGGACAGCACCTCCGACCCTGGCGTACAGCTCGTCCAGGCCGCACCC
 91 1 Gl ySer Al aAspArgPheAsnThr Ser Val Val Gl uSer TrpGl uAl aTyrLeuGl uAspLeuGl yArgVal Tr
 2294 ACACCCAGGCCAGGGTGTGTCGGCACACCTGGCTGGACCGCGTGTGAACAGGGTCACGTCGTCCGG
 66 1 pVal TrpAl aLeuThrAsnAspProVal Val Gl nAspGl nVal Al aSer l lePheLeuThr Val AspAspArgV

SmaI (2398)

2368 ACCACACCGCGAAGTCGTCCACGAAGTCCCAGGAGAACCCGAGCCGGTGGTCCAGAACTCGACCGCTCC
 41 1 al Val Gl yAl aPheAspAspGl uVal PheAspArgSer PheGl yLeuArgAspThr TrpPheGl uVal Al aGl y
 2442 GGCAGCTCGCGCGGTGAGCACCGAACGGCACTGGTCAACTGGCATGATGCCCTATAGTGAGTCG
 17 1 Al aVal AspArgAl aThr LeuVal ProVal Al aSer Thr LeuLysAl aMet ←

AseI (2546)

2516 TATTATACTATGCCGATATACTATGCCGATGATTAATTGTCAA AACAGCGTGGATGGCGTCTCCAGCTTATCT
 2589 GACGGTTCACTAACGAGCTCGCTTATATAGACCTCCCACCGTACACGCCCTACCGCCATTGGCGTCAATGGG

SpeI (2701)

2663 GCGGAGTTTACGACATTTGAAAGTCCGTTATTACTAGTCAAAACAAACTCCATTGACGTCAATGG
 2736 GGTGGAGACTTGGAAATCCCGTGAGTCAAACCGCTATCCACGCCATTGATGTACTGCCAAAACCGCATCAT

SnaBI (2829)

2809 CATGGTAATAGCGATGACTAATACGTAGATGACTGCCAAGTAGGAAAGTCCATAAGGTATGTACTGGCAT

NdeI (2934)

2883 AATGCCAGGCCATTACCGTCATTGACGTCAATAGGGGGGTACTTGGCATATGATACTTGTACT
 2957 GCCAAGTGGCAGTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCATTGGCGTTACTATGGG
 3031 AACATACGTATTGACGTCAATGGCGGGGTCGTTGGCGGTAGCCAGGCAGGCCATTACCGTAAGTT

PstI (3113) PacI (3120)

SdaI (3112)**BspLU11I (3130)**

3105 ATGTAACGCCCTGCAGGTTAA TTAAAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGG
 3176 CCGCGTTGCTGGCGTTTTCCATAGGCTCCGCCCTGACGAGCATACAAAAATCGACGCTCAAGTCAGAGG
 3250 TGGCGAAACCCGACAGGACTATAAGATAACCAGGCCTTCCCTGGAAAGCTCCCTCGTGCCTCTGTTCC
 3324 GACCCCTGCCCTTACCGGATACTGTCCGCCCTTCTCCCTGGAAAGCGTGGCGCTTCTCATAGCTCACGCT
 3398 GTAGGTATCTCAGTCGGTAGGTCGCTCCAAGCTGGCTGTGACGAACCCCCGTTAGCCGAC
 3472 CGCTGCCCTTACCGTAACTATCGTCTGAGTCCAACCCGTAAGACACGACTTATGCCACTGGCAGCAGC
 3546 CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCCTGCTACAGAGTTCTGAAGTGGCTTAACACTACG
 3620 GCTACACTAGAAGAACAGTATTGGTATCTGCCTGCTGAAGCCAGTTACCTCGGAAAAAGAGTTGGTAGC
 3694 TCTTGATCCGGAAACAAACCAACCGCTGGTAGCGGTGGTTTTGTTGCAAGCAGCAGATTACGCGCAGAAA
 3768 AAAAGGATCTCAAGAAGATCCTTGATCTTCTACGGGTCTGACGCTCAGTGGAACGAAAACACGTTAAG

PacI (3860)

3842 GGATTTGGTCATGGCTAGTTAATTAACATTAAATC A